LynxDx Revenue and Competitors

Detroit, MI USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • LynxDx's estimated annual revenue is currently $18M per year.(i)
  • LynxDx's estimated revenue per employee is $155,000

Employee Data

  • LynxDx has 116 Employees.(i)
  • LynxDx grew their employee count by -8% last year.

LynxDx's People

NameTitleEmail/Phone
1
Chief Commercial OfficerReveal Email/Phone
2
VP Research and DevelopmentReveal Email/Phone
3
VP Finance and Human ResourcesReveal Email/Phone
4
VP SalesReveal Email/Phone
5
Director Client ExperienceReveal Email/Phone
6
Regional Sales DirectorReveal Email/Phone
7
Director Key AccountsReveal Email/Phone
8
Director Key AccountsReveal Email/Phone
9
Medical DirectorReveal Email/Phone
10
Director OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.9M120%N/AN/A
#2
$2.6M34-56%$31.2MN/A
#3
$0.8M5-44%N/AN/A
#4
$1.9M24100%N/AN/A
#5
$6M39-11%N/AN/A
#6
$4M26-33%N/AN/A
#7
$1.9M120%N/AN/A
#8
$0.8M525%N/AN/A
#9
$14.6M948%N/AN/A
#10
$3.4M225%N/AN/A
Add Company

What Is LynxDx?

LynxDx is working to commercialize a prostate cancer urine diagnostic assay that is able to confidently prevent many unnecessary prostate biopsies. The test, called the MyProstateScore (MPS), is performed in a regulatory-compliant commercial laboratory. To assist in the global response to the COVID-19 pandemic, LynxDx has worked aggressively to repurpose our clinical laboratory infrastructure to offer diagnostic COVID-19 testing.

keywords:N/A

N/A

Total Funding

116

Number of Employees

$18M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

LynxDx News

2022-04-13 - Detroit school district to dial back COVID testing

Vitti said the contract with LynxDX provides the district with an option to expand testing in case COVID cases surge during the 2022-23 school...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.9M1169%N/A
#2
$7.5M1184%N/A
#3
$21.4M11986%N/A
#4
$42.4M120-2%N/A
#5
N/A1209%N/A